Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

被引：0
|
作者：
Jenny Zheng
Yanke Yu
Chandrasekar Durairaj
Véronique Diéras
Richard S. Finn
Diane D. Wang
机构：
[1] Pfizer Inc,Pharmacometrics, Global Product Development
[2] Col-D/006/D6400,Clinical Pharmacology
[3] Global Product Development,Department of Medical Oncology Institut Curie
[4] Pfizer Inc,undefined
[5] Paris and Centre Eugène Marquis,undefined
[6] David Geffen School of Medicine at UCLA,undefined
来源：
Targeted Oncology | 2021年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：69 / 76
页数：7
相关论文
共 50 条
  • [1] Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
    Zheng, Jenny
    Yu, Yanke
    Durairaj, Chandrasekar
    Dieras, Veronique
    Finn, Richard S.
    Wang, Diane D.
    [J]. TARGETED ONCOLOGY, 2021, 16 (01) : 69 - 76
  • [2] Population Pharmacokinetics, Efficacy Exposure-Response Analysis
    Chan, Phyllis
    Yu, Jiajie
    Chinn, Leslie
    Prohn, Marita
    Huisman, Jan
    Matzuka, Brett
    Hanley, William
    Tuckwell, Katie
    Quartino, Angelica
    [J]. PHARMACEUTICAL RESEARCH, 2020, 37 (02)
  • [3] Abatacept Exposure-Response Analysis and its Impact on Dose Selection in Lupus Nephritis
    Suryawanshi, Satyendra
    Tagen, Michael
    Murthy, Bindu
    Hillson, Jan
    Roy, Amit
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S48 - S48
  • [4] ABATACEPT EXPOSURE-RESPONSE ANALYSIS AND ITS IMPACT ON DOSE SELECTION IN LUPUS NEPHRITIS
    Suryawanshi, S.
    Tagen, M.
    Murthy, B.
    Hillson, J.
    Roy, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 480 - 480
  • [5] Exposure-Response Analysis Demonstrates Predicted Exposure for Clinical Efficacy with Pridopidine 45-mg Bid Dose
    Geva, Michal
    McGarry, Andrew
    Gershoni-Emek, Noga
    Olanow, C. Warren
    Kieburtz, Karl
    Hayden, Michael R.
    [J]. NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 22 - 22
  • [6] Exposure-response relationship for the efficacy of fesoterodine
    El-Tahtawy, A.
    Malhotra, B.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 100 - 100
  • [7] An Exposure-Response Perspective on the Clinical Dose of Pretomanid
    Nedelman, Jerry R.
    Salinger, David H.
    Subramoney, Vishak
    Woolson, Rob
    Wade, Karen
    Li, Mengchun
    Everitt, Daniel
    Mendel, Carl M.
    Spigelman, Mel
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (01)
  • [8] Dose- and Exposure-Response to Ketamine in Depression
    Glue, Paul
    Gulati, Abhishek
    Le Nedelec, Martin
    Duffull, Stephen
    [J]. BIOLOGICAL PSYCHIATRY, 2011, 70 (04) : E9 - E10
  • [9] Use of a Biomarker in Exposure-Response Analysis to Support Dose Selection for Fingolimod
    Lee, J-Y
    Wang, Y.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (08):
  • [10] Impact of the specificity of the exposure metric on exposure-response relationships
    Friesen, Melissa C.
    Davies, Hugh W.
    Teschke, Kay
    Ostry, Aleck S.
    Hertzman, Clyde
    Demers, Paul A.
    [J]. EPIDEMIOLOGY, 2007, 18 (01) : 88 - 94
12345